Skip to main content

Table 3 Prevalence of mental health alterations and lipodystrophy symptoms by gender 

From: Lipodystrophy among HIV-infected patients: a cross-sectional study on impact on quality of life and mental health disorders

  Male N (%) Female N (%) p value
Presence of depression (BDI score ≥19)a 28 (26.9) 40 (46.0) 0.006*
Presence of anxiety (STAI-Y-B score ≥46)b 44 (42.7) 55 (62.5) 0.006*
Poor QoL (≤50% visual score)c 43 (41.4) 50 (59.5) 0.013*
Severe LD (LDCD score ≥23 points)d 21 (28.8) 10 (16.1) 0.082
HOPS score:e
 Atrophy observed by patients 66 (72.5) 40 (52.6) 0.008*
 Atrophy observed by physicians 46 (60.0) 25 (37.3) 0.007*
 Hypertrophy observed by patients 47 (51.1) 59 (76.6) 0.001*
 Hypertrophy observed by physicians 35 (46.7) 44 (63.8) 0.039*
  1. aPresence of depression: according to Beck Depression Inventory score by Beck definition (BDI).
  2. bPresence of anxiety: according to State Trait Anxiety Inventory by Spielberger definition (STAI-Y-B).
  3. cQuality of Life Quantitative scale numbered 0%–100 according to the short version of EQ-5D-3L score.
  4. dSevere LD: according to LDCD score Lipodystrophy Case Definition by Carr et al.
  5. eAtrophy/Hypertrophy observed by patients/physicians: according to HOPS score by Lichtenchtein et al.
  6. * Significant p-value <0.05.